EMAIL THIS PAGE TO A FRIEND

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

A 12-year survey of methicillin-resistant Staphylococcus aureus infections in Greece: ST80-IV epidemic?


PMID 24750462

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of both healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA) infections. Severe MRSA infections have been associated with the virulence factor Panton-Valentine leukocidin (PVL). The aim of this study was to investigate susceptibility patterns, the presence of toxin genes, including that encoding PVL, and clonality among MRSA isolates collected from patients in Greece over a 12-year period. MRSA isolates were collected from January 2001 to December 2012 from six different hospitals. Antibiotic susceptibility was determined with the disk diffusion method and the Etest. The presence of the toxic shock syndrome toxin-1 gene (tst), the enterotoxin gene cluster (egc) and the PVL gene was tested with PCR. The genotypic characteristics of the strains were analysed by SCCmec and agr typing, and clonality was determined with pulsed-field gel electrophoresis and multilocus sequence typing. An increasing rate of MRSA among S.xa0aureus infections was detected up to 2008. The majority of PVL-positive MRSA isolates belonged to a single clone, sequence type (ST)80-IV, which was disseminated both in the community and in hospitals, especially during the warmest months of the year. Carriage of tst was associated with ST30-IV, whereas egc was distributed in different clones. CA-MRSA isolates were recovered mainly from skin and soft tissue infections, whereas HA-MRSA isolates were associated with surgical and wound infections. During the period 2001-2012, ST80-IV predominated in the community and infiltrated the hospital settings in Greece, successfully replacing other PVL-positive clones. The predominance of ST239-III in HA-MRSA infections was constant, whereas new clones have also emerged. Polyclonality was statistically significantly higher among CA-MRSA isolates and isolates from adult patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D2446
Daptomycin, cyclic lipopeptide antibiotic
C72H101N17O26
E6376
Erythromycin, potency: ≥850 μg per mg
C37H67NO13
E5389
Erythromycin, BioReagent, suitable for cell culture
C37H67NO13
45674
Erythromycin, tested according to Ph.Eur.
C37H67NO13
PHR1039
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
C37H67NO13
E1300000
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
C37H67NO13
1242000
Erythromycin, United States Pharmacopeia (USP) Reference Standard
C37H67NO13
E0774
Erythromycin, meets USP testing specifications
C37H67NO13
E4514
Erythromycin, plant cell culture tested, ~98%
C37H67NO13
45703
Erythromycin standard solution, 1 mg/mL in H2O
C37H67NO13
F0756
Fusidic acid
C31H48O6
Y0001411
Fusidic acid, European Pharmacopoeia (EP) Reference Standard
C31H48O6
Y0001394
Fusidic acid for peak identification, European Pharmacopoeia (EP) Reference Standard
C31H48O6
PZ0014
Linezolid, ≥98% (HPLC)
C16H20FN3O4
R3501
Rifampicin, ≥97% (HPLC), powder
C43H58N4O12
R8883
Rifampicin, powder, γ-irradiated
C43H58N4O12
46713
Rifampicin, VETRANAL, analytical standard
C43H58N4O12
R0700000
Rifampicin, European Pharmacopoeia (EP) Reference Standard
C43H58N4O12
T4014
Tobramycin, Aminoglycoside antibiotic
C18H37N5O9
PHR1079
Tobramycin, Pharmaceutical Secondary Standard; Certified Reference Material
C18H37N5O9
T1500000
Tobramycin, European Pharmacopoeia (EP) Reference Standard
C18H37N5O9
1667508
Tobramycin, United States Pharmacopeia (USP) Reference Standard
C18H37N5O9
T7883
Trimethoprim, ≥98% (HPLC)
C14H18N4O3
46984
Trimethoprim, VETRANAL, analytical standard
C14H18N4O3
92131
Trimethoprim, crystallized, ≥99.0% (HPLC)
C14H18N4O3
PHR1056
Trimethoprim, Pharmaceutical Secondary Standard; Certified Reference Material
C14H18N4O3
1692505
Trimethoprim, United States Pharmacopeia (USP) Reference Standard
C14H18N4O3
T2200000
Trimethoprim, European Pharmacopoeia (EP) Reference Standard
C14H18N4O3
Y0000684
Trimethoprim for system suitability, European Pharmacopoeia (EP) Reference Standard
C14H18N4O3